February 6th 2025
In a randomized control study, the antiviral demonstrated reduced risk and could potentially influence treatment management for patients with a moderate or high viral load.
December 29th 2024
The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.
Read More
FDA Approves Paxlovid for COVID-19 in Adults, Continues Strategy to Minimize Infection Severity
May 25th 2023This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Read More
FDA Approves Sulbactam-Durlobactam for Bacterial Pneumonia
May 23rd 2023The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
Read More
Expanding HCV Care: Effectiveness of Accessible Testing and Treatment for People Who Inject Drugs
May 20th 2023By implementing rapid point-of-care HCV RNA testing in supervised consumption services, a study achieved high testing acceptance and successful engagement with HCV care among individuals who inject drugs.
Read More
AI-Driven Advancements Pave the Way to Test for COVID-19 and Hepatitis at Home
May 18th 2023These new tests, conducted in a single tube within minutes, could enable at-home testing for various diseases. By incorporating CRISPR technology, the test achieves high reliability by distinguishing between false and true positives.
Read More
Using AI as a Tool for Infectious Disease Surveillance
May 17th 2023AI tools have taken front and center stage in 2023. One area of interest is how the new technology can be applied in infectious disease surveillance. A new article in the New England Journal of Medicine explores this concept.
Read More
Preparing for AUR Reporting Mandates to Capitalize on Quality Reimbursement
May 15th 2023The mandatory reporting of Antimicrobial Use and Resistance (AUR) by hospitals participating in the CMS Medicare Promoting Interoperability Program beginning next year is a important strategy in curbing the overuse of antibiotics.
Read More
With Hepatitis Month, a Reminder of Accomplishments, but Still Work to Do
May 10th 2023May marks Hepatitis Awareness Month. There is a lot to be thankful for, as there has been a lot of inroads made in terms of curative therapy, vaccine development, and now the federal government is putting a major emphasis on getting people into the continuum of care. Still education is needed to help prevent the silent killer.
Read More